Day One Biopharmaceuticals, Inc. (DAWN) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 331 transactions totaling $162.8M, demonstrating a bullish sentiment with $17.5M in net insider flow. The most recent transaction on Nov 25, 2025 involved a transaction of 7,225 shares valued at $0.
No significant insider buying has been recorded for DAWN in the recent period.
No significant insider selling has been recorded for DAWN in the recent period.
Based on recent SEC filings, insider sentiment for DAWN is bullish with an Insider Alignment Score of 55/100 and a net flow of $17.5M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Day One Biopharmaceuticals, Inc. (DAWN) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading DAWN stock, having executed 331 transactions in the past 90 days. The most active insider is Len Blavatnik (Executive), who has made 2 transactions totaling $28.0M.
Get notified when executives and directors at DAWN file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 7,225 | $N/A | $0 | |
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 300,000 | $N/A | $0 | |
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 300,000 | $N/A | $0 | |
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 300,000 | $N/A | $0 | |
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 7,225 | $N/A | $0 | |
| Nov 25, 2025 | Bender Jeremy | Executive | Gift | 300,000 | $N/A | $0 | |
| Nov 17, 2025 | Bender Jeremy | Executive | Sale | 15,894 | $8.91 | $141.6K | |
| Nov 17, 2025 | Merendino Lauren | Executive | Sale | 3,726 | $8.91 | $33.2K | |
| Nov 17, 2025 | N. York Charles II | Executive | Sale | 4,062 | $8.91 | $36.2K | |
| Nov 17, 2025 | Dubow Adam | Executive | Sale | 4,319 | $8.91 | $38.5K | |
| Nov 15, 2025 | Bender Jeremy | Executive | Option Exercise | 11,687 | $N/A | $0 | |
| Nov 15, 2025 | Bender Jeremy | Executive | Option Exercise | 11,687 | $N/A | $0 | |
| Nov 15, 2025 | Bender Jeremy | Executive | Option Exercise | 4,750 | $N/A | $0 | |
| Nov 15, 2025 | Bender Jeremy | Executive | Option Exercise | 3,570 | $N/A | $0 | |
| Nov 15, 2025 | Merendino Lauren | Executive | Option Exercise | 3,687 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 17 | $90.1M | 55.4% |
Sale(S) | 160 | $72.7M | 44.6% |
Gift(G) | 38 | $0 | 0.0% |
Exercise(M) | 98 | $0 | 0.0% |
Other(J) | 11 | $0 | 0.0% |
Conversion(C) | 7 | $0 | 0.0% |
Insider activity at Day One Biopharmaceuticals, Inc. shows mixed signals across all time. While $90.1M in purchases indicates some executive confidence,$72.7M in sales balances the picture, resulting in a modest net flow of $17.5M.22 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Len Blavatnik, has transacted $28.0M during this period.